BARZOLVOLIMAB
UNII 4B77GX0NA3

Substance Identification & Data

This profile provides standardized clinical and technical data for Barzolvolimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 4B77GX0NA3.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2438203-51-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

4B77GX0NA3

CAS Registry Number

2438203-51-9

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

BARZOLVOLIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C184860

National Cancer Institute reference terminology for clinical and research data.

INN ID

11842

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

KL-133

Identifier assigned by the United States Adopted Names Council.

Substance Type

Barzolvolimab

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Barzolvolimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Barzolvolimab

Common Names & Synonyms

BARZOLVOLIMAB [USAN]

Barzolvolimab [WHO-DD]

Immunoglobulin G1 [233-alanine,234-glutamine,251-tyrosine,253-threonine,255-glutamic acid,321-glutamine,de-C-terminal-lysine], anti-(human receptor tyrosine kinase KIT extracellular domain) (human-Mus musculus monoclonal CDX-0159 γ1-chain), disulfide with human-Mus musculus monoclonal CDX-0159 κ-chain, dimer

barzolvolimab [INN]

immunoglobulin G1-kappa, anti-[Homo sapiens KIT (KIT protooncogene receptor tyrosine kinase, c-kit, c-Kit, SCFR, CD117) extracellular domain], monoclonal antibody; gamma1 heavy chain (1-445) [VH Musmus/Homsap (Mus musculus IGHV1-76*01 (87.8%) -(IGHD) -IGHJ2*01 (93.3%) L124>V (112)/Homo sapiens IGHV1-2*06 (76.5%) -(IGHD) -IGHJ4*01 (93.3%) L123>T (111), CDR-IMGT [8.8.9] (26-33.51-58.97-105)) (1-116) -Homo sapiens IGHG1*01, G1m17,1, G1v21 CH2 Y15.1, T16, E18, G1v20 CH2 A105 (CH1 K120 (213) (117-214), hinge 1-15 (215-229), CH2 L1.3>A (233), L1.2>Q (234), M15.1>Y (251), S16>T (253), T18>E (255), K105>Q (321) (230-339), CH3 D12 (355), L14 (357) (340-444), CHS K>del (445)) (117-445)], (219-214')-disulfide with kappa light chain (1'-214') [V-KAPPA Musmus/Homsap (Mus musculus IGKV6-15*01 (84.2%) - IGKJ1*01 (90.9%) L124>V (104)/Homo sapiens IGKV1-16*01 (81.1%) - IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'- 214')]; dimer (225-225'':228-228'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Technical Codes

CDX-0159

External Clinical & Regulatory Resources

Previous UNII4B76B4TY86

Next UNII4B7KRX7E7M